FDA Approval Sought for Abiraterone Acetate for Early-Stage Metastatic Prostate Cancer

September 15, 2017 – A supplemental new drug application has been submitted for abiraterone acetate in combination with prednisone and androgen deprivation therapy (ADT) for high-risk patients with metastatic hormone-naïve prostate cancer (HNPC) or newly-diagnosed metastatic hormone-sensitive prostate cancer (HSPC), according to a statement from the company developing therapy, Janssen Biotech. The application was based on findings from the phase … (leggi tutto)